Please login to the form below

bosentan

This page shows the latest bosentan news and features for those working in and with pharma, biotech and healthcare.

J&J agrees $30bn deal to acquire Actelion

Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs

Latest news

Actelion reports late-stage trial failure as J&J talks continue

Tracleer (bosentan) which has lost patent protection in the US and Europe.
J&J back in frame to buy Actelion after Sanofi talks break down

Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH
J&J abandons talks with Actelion as another suitor circles

After a challenging couple of years following the loss of patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), Actelion is now riding high on the back of strong growth
Resurgent Actelion catches J&J's eye

Actelion's top-selling product Tracleer (bosentan) has already lost patent protection in some markets and saw sales slide 15% in the first nine months of the year to CHF 790m (
Actelion gets EU go-ahead for Uptravi in PAH

Tracleer (bosentan).

More from news
Approximately 4 fully matching, plus 22 partially matching documents found.

Latest appointments

J&J's Jane Griffiths named global head of Actelion

At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).
New associate director at Packer Forbes

Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Executive – Medical Communications: Salary TBC

Associate Medical Director: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Editorial Director – Medical Education: Neg

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Director Healthcare PR Communications: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Director – Head of Public Affairs: Neg

Account Director - Digital: Great salary and benefits

Experienced Editor, London, Medical Communications: Competitive package

Account Director – Global Healthcare PR: Salary TBC

Account Director: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Director: Highly Competitive Salary &Benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Scientific Team Lead: Competitive Salary

Associate Medical Director: Highly Competitive

Subscribe to our email news alerts

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...